Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone

Free Abstracts


  Free Subscription


4 Am J Hematol
2 Ann Hematol
5 Blood
1 Cancer
1 Gene
1 Genes Chromosomes Cancer
1 Int J Hematol
1 J Immunol
1 J Pediatr Hematol Oncol
7 Leuk Lymphoma
1 Leuk Res
1 Leukemia
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Hematol

  1. BAIN BJ
    Pure erythroid leukemia: the need gather data on this condition as defined in the World Health Organisation classification.
    Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24863.
    PubMed     Text format    

  2. VALLAPUREDDY R, Lasho TL, Hoversten K, Finke CM, et al
    Nucleophosmin 1 (NPM1) Mutations in Chronic Myelomonocytic Leukemia and Their Prognostic Relevance.
    Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24861.
    PubMed     Text format    

  3. WANG W, Wang S, Medeiros LJ, Khoury JD, et al
    Response to Dr. Bain's comment on our review article: Pure Erythroid Leukemia.
    Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24862.
    PubMed     Text format    

  4. JAROSOVA M, Hruba M, Oltova A, Plevova K, et al
    Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients.
    Am J Hematol. 2017 Jul 11. doi: 10.1002/ajh.24852.
    PubMed     Text format    

    Ann Hematol

  5. NISCOLA P, Tendas A, Abruzzese E, Caravita T, et al
    Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice.
    Ann Hematol. 2017 Jul 12. doi: 10.1007/s00277-017-3064.
    PubMed     Text format    

  6. THOMAY K, Fedder C, Hofmann W, Kreipe H, et al
    Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions.
    Ann Hematol. 2017 Jul 9. doi: 10.1007/s00277-017-3055.
    PubMed     Text format     Abstract available


  7. CARPENTER PA, Johnston L, Fernandez HF, Radich JP, et al
    Post-transplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia.
    Blood. 2017 Jul 11. pii: blood-2017-03-771121. doi: 10.1182/blood-2017-03-771121
    PubMed     Text format    

  8. SCHEWE DM, Alsadeq A, Sattler C, Lenk L, et al
    An Fc engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.
    Blood. 2017 Jul 11. pii: blood-2017-01-764316. doi: 10.1182/blood-2017-01-764316
    PubMed     Text format     Abstract available

  9. TALSMA CE, Boyer DF
    Myeloid leukemia associated with Down syndrome.
    Blood. 2017;130:230.
    PubMed     Text format    

  10. THAKRAL B, Muzzafar T
    Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
    Blood. 2017;130:231.
    PubMed     Text format    

  11. Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702-2705.
    Blood. 2017;130:232.
    PubMed     Text format    


  12. JABBOUR E, Short NJ, Ravandi F, Huang X, et al
    A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
    Cancer. 2017 Jul 14. doi: 10.1002/cncr.30883.
    PubMed     Text format     Abstract available


  13. GERVASINI G, de Murillo SG, Jimenez M, de la Maya MD, et al
    Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gene. 2017 Jul 11. pii: S0378-1119(17)30538-3. doi: 10.1016/j.gene.2017.
    PubMed     Text format     Abstract available

    Genes Chromosomes Cancer

  14. YAMATO G, Yamaguchi H, Handa H, Shiba N, et al
    Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia.
    Genes Chromosomes Cancer. 2017 Jul 14. doi: 10.1002/gcc.22483.
    PubMed     Text format     Abstract available

    Int J Hematol

  15. REA D, Cayuela JM
    Treatment-free remission in patients with chronic myeloid leukemia.
    Int J Hematol. 2017 Jul 8. doi: 10.1007/s12185-017-2295.
    PubMed     Text format     Abstract available

    J Immunol

  16. SKOPELJA-GARDNER S, Jones JD, Hamilton BJ, Danilov AV, et al
    Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
    J Immunol. 2017 Jul 14. pii: ji1602105. doi: 10.4049/jimmunol.1602105.
    PubMed     Text format     Abstract available

    J Pediatr Hematol Oncol

  17. DE LEONARDIS F, Perillo T, Daniele RM, Santoro N, et al
    Cytomegalovirus Cavitary Pneumonia in Nontransplant Pediatric Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
    J Pediatr Hematol Oncol. 2017 Jul 10. doi: 10.1097/MPH.0000000000000901.
    PubMed     Text format     Abstract available

    Leuk Lymphoma

  18. SAYGIN C, Papadantonakis N, Cassaday RD, Liedtke M, et al
    Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.
    Leuk Lymphoma. 2017 Jul 11:1-9. doi: 10.1080/10428194.2017.1344842.
    PubMed     Text format     Abstract available

  19. DAMLAJ M, Al Balwi M, Al Mugairi AM
    Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
    Leuk Lymphoma. 2017 Jul 11:1-4. doi: 10.1080/10428194.2017.1347653.
    PubMed     Text format    

  20. GARRISI VM, Sgherza N, Breccia M, Iacobazzi A, et al
    Association between proteomic profile and molecular response in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2017 Jul 11:1-3. doi: 10.1080/10428194.2017.1344841.
    PubMed     Text format    

  21. KREMER B, Tsai DE, Debonera F, Cohen PL, et al
    Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide.
    Leuk Lymphoma. 2017 Jul 11:1-3. doi: 10.1080/10428194.2017.1347652.
    PubMed     Text format    

  22. WILLIAMS AM, Baran AM, Meacham PJ, Feldman MM, et al
    Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
    Leuk Lymphoma. 2017 Jul 11:1-8. doi: 10.1080/10428194.2017.1347931.
    PubMed     Text format     Abstract available

  23. CHELYSHEVA E, Turkina A, Polushkina E, Shmakov R, et al
    Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment.
    Leuk Lymphoma. 2017 Jul 13:1-6. doi: 10.1080/10428194.2017.1347929.
    PubMed     Text format     Abstract available

  24. HOROWITZ NA, Henig I, Henig O, Benyamini N, et al
    Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis.
    Leuk Lymphoma. 2017 Jul 13:1-7. doi: 10.1080/10428194.2017.1347651.
    PubMed     Text format     Abstract available

    Leuk Res

  25. ALABDULWAHAB AS, Elsayed HG, Sherisher MA, Zeeneldin A, et al
    The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
    Leuk Res. 2017;60:58-62.
    PubMed     Text format     Abstract available


  26. ZHANG Q, Ball MC, Zhao Y, Balasis M, et al
    Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.
    Leukemia. 2017 Jun 21. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available

    PLoS One

  27. ALONSO-DOMINGUEZ JM, Casado LF, Anguita E, Gomez-Casares MT, et al
    PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.
    PLoS One. 2017;12:e0181366.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.